Found 74 Enz. Inhib. hit(s) with all data for entry = 11021 TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: <1nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 1.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
TargetIsoform Truncated 1 of E3 ubiquitin-protein ligase CBL-B [36-427] (Homo sapiens (Human))
Nurix Therapeutics
US Patent
Nurix Therapeutics
US Patent
Affinity DataIC50: 3.5nMAssay Description:The ability of candidate compounds to displace a known inhibitor and thereby inhibit Cbl-b activity was measured by monitoring the interaction of Cbl...More data for this Ligand-Target Pair
